

Fecal Microbiota Transplantation

Subjects: Gastroenterology & Hepatology

Contributor: Francesca Romana Ponziani

Among all the methods available to achieve this purpose, fecal microbiota transplantation (FMT) is one of the most promising, being able to directly reshape the recipient's gut microbial communities.

Keywords: gut microbiota ; gut-liver axis ; liver disease ; fecal microbiota transplantation

1. Introduction

Liver cirrhosis represents the end stage of all chronic liver diseases, including chronic hepatitis B virus (HBV) infection, and is the hallmark of gut dysbiosis. This supports the hypothesis that alterations of the gastrointestinal system in patients with advanced liver disease contribute to the gut microbiota derangement ^{[1][2]}. Changes in the composition of bile acids secreted into the intestine as a consequence of liver dysfunction are also implied in the gut microbiota derangement and in the maintenance of liver damage ^{[3][4]}. Primary bile acids represent a metabolic substrate for intestinal bacteria, which in turn produce secondary bile acids that can act as a regulator of the gut microbiota itself.

The alteration of the gut microbiota causes intestinal inflammation and worsens the damage to the gut barrier; in addition, the translocation of bacterial fragments and their metabolites can trigger liver injury and systemic inflammation ^[5]. Several studies have associated changes in the gut microbiota with liver cirrhosis and its complications, in particular hepatic encephalopathy (HE) ^[6].

It is also possible that in some individuals dysbiosis could precede the onset of liver disease, and may represent the first hit in the development of hepatic injury.

Although it is difficult to clarify whether the chicken or egg came first, the role of the gut microbiota in the pathogenesis of liver disease is crucial and, therefore, its modulation by fecal microbiota transplantation (FMT) is a promising therapeutic and, perhaps, preemptive option for these patients. The aim of this review is to provide an update on the current knowledge regarding the efficacy and safety of FMT in patients with hepatic encephalopathy and with chronic HBV infection or other chronic liver diseases.

2. FMT for Hepatic Encephalopathy

In cirrhotic patients with HE, the gut microbiota composition is characterized by an increase in potentially pathogenic bacteria, mostly *Alcaligenaceae*, *Porphyromonadaceae*, *Veillonellaceae*, and *Enterobacteriaceae*, and by a decreased abundance of commensal ones, such as *Lachnospiraceae*, *Ruminococcaceae*, and *Blautia*, compared to patients with compensated cirrhosis ^{[7][8][9]}. In addition, the translocation of bacteria and their fragments, endotoxin, and DNA triggers a systemic inflammatory response, which acts synergistically with bacterial metabolic products in the development and progression of cognitive impairment in patients with HE ^{[10][11]}. Less complex correlations between bacteria and phages have been observed in cirrhotic patients with HE compared to controls, and hospitalization was associated with enrichment of *Streptococcus*-linked phages ^[12]. Urease is essential in bacterial colonization and is a virulence factor of several pathogenic bacteria

FMT can be a promising tool in association with the standard of care (lactulose, rifaximin) for the modulation of the gut microbiota in patients with HE.

All donor materials, instilled by enema, came from a single individual that was selected based on machine learning techniques to identify the highest relative abundances of *Lachnospiraceae* and *Ruminococcaceae* among a universal stool donor bank. HE recurred in 50% of patients in the standard of care (SOC) group, but no recurrence was observed in those who received FMT; FMT was also associated with a lower rate of hospitalizations and a higher improvement in cognitive tests. This was paralleled by the increase in microbial alpha diversity as well as in the relative abundance of

beneficial taxa (Lactobacillaceae and Bifidobacteriaceae) compared to the SOC arm. Safety and efficacy were still maintained at 1-year from the procedure, with significantly more episodes of hospitalizations and HE occurring in the SOC arm compared to the FMT one [13].

The same group of Authors reported on the safety and tolerability of FMT with oral capsules in patients with recurrent HE in a randomized, single-blind, placebo-controlled trial (Table 1) [14]. Using the same criteria of the previous study for donor selection, 20 patients were randomized 1:1 to receive 15 capsules of FMT or placebo. However, HE episodes recurrence rates were similar between groups, and only one of the cognitive tests performed (EncephalApp) showed a significant improvement after FMT. Indeed, in stool samples a reduction in potentially pathogenic bacteria (Veillonellaceae and Sutterellaceae) was observed; furthermore, the analysis of duodenal biopsy revealed a drop in potentially pathogenic bacteria (Streptococaceae and Veillonellaceae) as well as an increase in beneficial ones (Ruminococcaceae and Bifidobacteriaceae) [13].

Table 1. Evidence on fecal microbiota transplantation (FMT) in patients with chronic liver disease.

Setting	Study Design	Groups	Type of FMT	Safety Outcomes	Efficacy Outcomes
Bajaj et al., (2017 and 2019) [15][13]	Recurrent HE in cirrhosis	Open-label, randomized clinical	FMT + SOC (10) vs. SOC (10)	Three FMT units instilled by enema	<p>Patient with SAEs: 2 vs. 8 ($p = 0.02$)</p> <p>Total SAEs: 2 vs. 11 ($p = 0.01$)</p> <p>Total HE episodes: 0 vs. 6 ($p = 0.03$)</p> <p>Improvement in PHES total score:</p> <ul style="list-style-type: none"> - In FMT group ($p = 0.03$) - In SOC group ($p = 0.98$) <p>Improvement in EncephalApp Stroop:</p> <ul style="list-style-type: none"> - In FMT group ($p = 0.01$) - In SOC group ($p = 0.26$) <p>Long-term impact of FMT (12–15 months):</p> <ul style="list-style-type: none"> - Hospitalization: 1 vs. 10 ($p = 0.05$) - Total HE events: 0 vs. 8 ($p = 0.03$)
Bajaj et al., (2019) [14]	Recurrent HE in cirrhosis	Randomized, single-blind, placebo-controlled	FMT + SOC (10) vs. placebo + SOC (10)	15 FMT capsules	<p>Patient with SAEs: 1 vs. 6</p> <p>Total SAEs: 1 vs. 11</p> <p>Patient with self-limited AEs: 4 vs. 3</p> <p>Total HE episodes: 1 vs. 7</p> <p>HE episodes requiring hospitalization/ER visit: 1 vs. 7</p>
Ren et al., (2017) [16]	HBeAg-positive CHB	Pilot study	AVT + FMT (5) vs. AVT (13)	FMT in duodenum, every 4 weeks until HBeAg clearance was achieved (one to seven FMT)	<p>Adverse events: 0/5</p> <p>HBeAg clearance: 4/5 vs. 0/13 ($p = 0.001$)</p> <p>HBsAg seroconversion: 0/5 vs. 0/13</p>
Chauhan et al., (2020) [17]	HBeAg-positive CHB	Pilot study	AVT + FMT (14) vs. AVT (15)	Six cycles of endoscopic FMT in duodenum, every four weeks (12/14 complete cycles)	<p>Minor adverse events: 6/14</p> <p>HBeAg clearance: 2/12 vs. 0/15 ($p = 0.188$)</p> <p>HBsAg loss: 0/14 vs. 0/15</p> <p>HBV-DNA suppression: 1/4 vs. 0/2</p>
Philips et al., (2017) [18]	Severe AH	Pilot study	Steroids not eligible + FMT (8) vs. SOC (18)	Once daily FMT via nasoduodenal tube for 7 days	<p>1-year survival: 87.5% vs. 33.3% ($p = 0.018$)</p>

	Setting	Study Design	Groups	Type of FMT	Safety Outcomes	Efficacy Outcomes
Philips et al., (2018) ^[19]	Severe AH	Retrospective	FMT (16) vs. corticosteroids (8), nutritional therapy (17) and, pentoxifylline (10)	Once daily FMT via nasoduodenal tube for 7 days		Survival in FMT vs. corticosteroids, nutritional therapy and pentoxifylline group: 30-day survival: 75% vs. 63, 47, and 40% ($p = 0.179$) 90-day survival: 75% vs. 29, 38 and 30% ($p = 0.036$)
Craven et al., (2020) ^[20]	NAFLD	Double-blinded randomized controlled	Allogenic FMT (15) vs. autologous FMT (6)	Single endoscopic FMT in duodenum		HOMA-IR score after 6 weeks: no significant decrease Hepatic PDFF after 6 months: no significant changes Small intestinal permeability after 6 weeks: improvement in allogenic group ($p = 0.018$)
Allegretti et al., (2019) ^[21]	PSC and concurrent IBD	Open-label pilot study	FMT (10)	Single endoscopic FMT in right colon	FMT-related AEs: 0/10	Decrease in ALP levels $\geq 50\%$: 3/10
Philips et al., (2018) ^[22]	PSC without IBD	Case report	-	Endoscopic FMT in duodenum, Once weekly for 4 weeks		

SOC = standard of care, HE = hepatic encephalopathy, SAEs = serious adverse events, AEs = adverse events, PHES = psychometric encephalopathy score, AH = alcoholic hepatitis, ER = emergency room, NAFLD = non-alcoholic fatty liver disease, HOMA-IR = homeostatic model assessment for insulin resistance, PDFF = proton density fat fraction, PSC = primary sclerosing cholangitis, IBD = inflammatory bowel disease, ALP = alkaline phosphatase, CHB = chronic B hepatitis, AVT = antiviral therapy.

With the limitation of the small sample size of these two studies, a lower gastrointestinal route preceded by administration of broad-spectrum antibiotics seems to favor FMT efficacy, being more effective to prevent HE recurrence. Considering the absence of significant SAEs, and the limited therapeutic options for patients with recurrent HE, further studies with larger sample sizes should be encouraged to clarify the best procedure to maximize the efficacy of FMT in cirrhotic patients with HE.

3. FMT for Different Etiologies of Liver Disease

The gut-liver axis could influence the host immune response to HBV, the susceptibility to hepatocyte damage, and the progression of liver disease to a more advanced stage of fibrosis.

Studies have demonstrated that changes in the gut microbiota may already be underway in the early phase of chronic HBV infection ^{[23][24]} and are mainly characterized by the reduction in *Alistipes* and *Bacteroides* compared to healthy subjects. This alteration of the gut microbiota results in the reduced production of SCFA and antibacterial peptides, consequently compromising the intestinal barrier ^[24]. Instead, Zeng et al. demonstrated that in chronic HBV hepatitis there was a higher abundance of *Bacteroidetes* and a lower abundance of *Firmicutes* and *Actinobacteria*, with enhanced activation of LPS-related pathways and disruption of the intestinal barrier ^[23].

analyzed gut microbiota alterations in healthy subjects, patients with chronic HBV infection, chronic HBV hepatitis, and liver cirrhosis, respectively. The results showed a dynamic shift of the gut microbiota profile during the progression of the disease. In particular, a progressive reduction in alpha-diversity was observed, as well as an increase in *Fusobacteria*, *Klebsiella*, *Veillonella*, and *Haemophilus* abundance, and a decrease in *Dialister succinatiphilus* and *Alistipes onderdonkii* in the late stage of liver disease ^[25].

Indeed, if minimal alterations of the gut microbiota are reported in patients with chronic HBV infection, the worsening of liver disease is associated with the decrease in beneficial species, such as *Roseburia* and *Ruminococcus*, and the increase in other potentially pathogenic species, such as *Escherichia*, *Shigella*, *Klebsiella*, *Enterococcus* and *Veillonella*. In patients affected by HBV-related acute or chronic liver failure, *Enterococcus*, *Klebsiella*, *Lactobacillus*, *Veillonella*, and *Escherichia-Shigella* become dominant [26].

A recent study assessed the gut microbiota composition in a mouse model of chronic HBV hepatitis, before and after treatment with entecavir, reporting that antiviral treatment can reverse dysbiosis developed in HBV-infected mice [27].

The pro-inflammatory alterations caused by dysbiosis in patients with HBV infection may contribute to the pathogenesis of hepatocellular carcinoma (HCC). Indeed, *Bacteroides*, *Lachnospiraceae* incertae sedis, and *Clostridium* XIVa are enriched in HCC patients with chronic HBV hepatitis and a high tumor burden [28].

Little evidence exists regarding the efficacy of FMT in chronic viral B hepatitis (**Table 1**). Ren et al. reported a pilot trial, analyzing the efficacy of FMT in 5 chronic hepatitis B patients treated with long-term antiviral therapy and without HBeAg clearance or seroconversion, compared to 13 chronic hepatitis B patients, in the same condition, who did not receive FMT. In the FMT group there was a significant HBeAg decline, nevertheless none achieved seroconversion. In contrast, none in the control group showed a decrease in HBeAg.

Another pilot study investigated the efficacy of FMT in achieving HBeAg clearance, HBsAg clearance, and reduction in HBV DNA serum level in HBeAg positive patients with chronic HBV hepatitis treated with long-term antiviral therapy (**Table 1**). Two out of 12 patients who received FMT obtained HBeAg clearance against none in the control group. In both groups, none of the patients achieved HBsAg clearance. After six months, a reduction in HBV DNA serum level was noticed in the FMT arm of patients with positive DNA at baseline, while no decrease was reported in the control group.

Two hypotheses can explain how HCV infection can influence the gut-liver axis [29][30]. On one hand, liver damage due to HCV infection changes liver function and, indirectly, the gut microbiota. On the other hand, HCV infection of B-lymphocyte and the consequent alteration of IgA production can lead to dysbiosis, increased bacterial translocation, and activation of inflammatory pathways that worsen the entity of liver damage and its progression to extensive fibrosis and cirrhosis.

HCV infected patients have lower bacterial diversity compared to healthy controls, with a decrease in *Clostridiales* (butyrate-producing bacteria), *Lachnospiraceae*, and *Ruminococcaceae* (SCFAs producers) and an increase in *Lactobacillus* and *Streptococcus* [31]. A transient increase in *Bacteroides* and *Enterobacteriaceae*, associated with proinflammatory effects, has been observed in patients with low fibrosis and normal serum levels of aminotransferases. *Streptococci* appeared to become abundant in the late stage of liver disease and were associated with a major risk of hyperammonaemia, while *S. salivarius* was especially increased in HCC patients [31].

In contrast with the previously published literature, Sultan et al. demonstrated an increased gut microbiota diversity in treatment-naïve patients with HCV infection compared to healthy controls, with a higher abundance of *Prevotella*, *Succinivibrio*, *Collinsella*, *Faecalibacterium*, *Coriobacteriaceae*, *Catenibacterium*, *Megasphaera*, *Mitsuokella multacida*, and *Ruminococcaceae*, and a lower abundance of *Bacteroides*, *Dialister*, *Alistipes*, *Bilophila*, *Streptococcus*, and *Enterobacteriaceae* [32].

Bajaj et al. reported that treatment with pegylated interferon and ribavirin achieved a sustained viral response (SVR), but did not improve gut microbiota composition, systemic inflammation, or endotoxemia [33]. Conversely, in another study, treatment with direct acting antivirals (DAAs) was able to modify the composition of the gut microbiota at least one year after the achievement of SVR, reducing gut dysbiosis and improving systemic inflammation, but without any effect on intestinal permeability [34]. Increased significantly 6–12 months after the achievement of SVR only in non-cirrhotic patients [35]. This confirms that treatment with DAAs can improve the gut microbiota profile in the short-term, especially in the early stage of liver disease, while in cirrhotic patients restoration of the gut microbiota may require more time.

Alcohol is a well-known disruptor of the intestinal barrier; acting on its components, such as mucus and tight junctions, it favors bacterial translocation as well as inflammation [7].

Indeed, a higher prevalence of bacterial overgrowth has been described [36], and the composition of the gut-microbiota is characterized by the reduction of beneficial bacteria, such as *Lactobacillus*, *Bifidobacterium* and *Ruminococcaceae*, and the increase in potentially pathogenic ones, such as *Veillonellaceae* and *Enterobacteriaceae* [37][38]. Llopis et al. showed that patients with severe alcoholic hepatitis had more *Bifidobacteria* and *Streptococci* than AUD patients without alcoholic hepatitis. Moreover, *Enterobacteria* and *Streptococci* were positively correlated with alcoholic hepatitis scores, and

Enterobacteria also correlated with serum bilirubin levels [39]. The dysbiosis due to alcohol abuse contributes to the occurrence and progression of alcoholic liver disease also through metabolic effects, such as modulating GABA and energy metabolism [40].

FMT has been mainly studied in the setting of alcoholic hepatitis (**Table 1**). Intriguingly, germ-free mice receiving the gut microbiota from a patient with severe alcoholic hepatitis developed more severe liver inflammation, higher liver necrosis, increased intestinal permeability, and bacterial translocation than mice receiving the gut microbiota from AUD patients without alcoholic hepatitis [39].

In a pilot study, 8 male patients with severe alcoholic hepatitis ineligible for steroid treatment underwent FMT through a nasoduodenal tube daily for 7 days (**Table 1**) [18]. FMT was safe and the bilirubin Child–Turcotte–Pugh score model for end-stage liver disease (MELD) improved significantly within the first week after FMT compared to a historical cohort of 18 patients with severe alcoholic hepatitis treated with the SOC during the same period. The 1-year survival rate was significantly better in the FMT group compared to the historical controls. The analysis of the gut microbiota showed changes in relative abundance of pathogenic species, such as *Klebsiella pneumoniae* (relative abundance change: from 10% to <1% at 1 year), and nonpathogenic ones, such as *Enterococcus villorum* (relative abundance change: from 9% to 23% at 6 months), *Bifidobacterium longum* (relative abundance change: from 6% to 50% at 6 months)

A retrospective study compared the outcomes of patients with severe alcoholic hepatitis treated with nutritional therapy (17), corticosteroids (8), pentoxifylline (10), or FMT (16) (**Table 1**) [19]. Patients undergoing FMT experienced a significantly higher 90-day survival compared to the other groups, with a durable beneficial modulation of the gut microbiota.

Based on these data, FMT could be a promising strategy to treat severe alcoholic hepatitis, however caution is required due to the small sample size of the available studies and the lack of randomized trials.

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic associated fatty liver disease (MAFLD) In particular, *Bacteroides* and *Ruminococcus* abundance correlate with the severity of liver inflammation and fibrosis [41]. Firmicutes can produce butyrate, which is a source of energy for enterocytes and helps to preserve gut permeability and avoid systemic inflammation [42]. This can worsen liver inflammation and steatohepatitis, especially in the case of higher sugar consumption, leading to the so called “auto-brewery syndrome” [43].

Specific gut microbiome signatures (e.g. reduction in Firmicutes and increase in *Escherichia coli* and Proteobacteria) able to predict the presence of advanced fibrosis have been used in patients with NAFLD [44]. More recently, Loomba et al. identified a gut microbiome signature able to predict the presence of NAFLD-cirrhosis with high accuracy (area under the curve (AUC) of 0.91). *Veillonella* and *Faecalibacterium* were the species with the highest discriminatory value. The model was effective in the prediction of cirrhosis independently of environmental and genetics factors, especially when incorporating clinical and laboratory parameters [45].

The consequent persistent stimulation of immune cells can favor the process of hepatocarcinogenesis through the exhaustion of the immune response, causing a kind of “immune paralysis”. This mechanism could be particularly true for the initiation of tumorigenesis, and may subsequently act as a trigger for the promotion of tumor cell proliferation, acting on the tumor microenvironment [46]. Another recent study investigated the correlation between gut microbiota signature, metabolomic profile and immune status in patient with MAFLD-HCC compared with MAFLD-cirrhosis. This signature was positively correlated with the production of short chain fatty acids (SCFAs), which exert immunomodulatory effects through the expansion of regulatory T cells and the decrease of CD8+T cells [47].

There are only a few studies on the efficacy of FMT in the context of NAFLD (**Table 1**). The same study showed that FMT could improve tight junctions, decrease endotoxin serum levels, and ameliorate steatohepatitis, leading to a significant decrease in intrahepatic lipid accumulation, intrahepatic pro-inflammatory cytokines, and improving the NAS score. In humans, a recent study analyzed the efficacy of FMT in patients with NAFLD in terms of a decrease in insulin resistance, measured with HOMA-IR score, reduction of liver fat content, evaluated measuring hepatic proton density fat fraction (PDFF) by magnetic resonance imaging (MRI), and improvement in small intestinal permeability assessed using the lactulose/mannitol test [20]. After FMT, there was no significant improvement in insulin sensitivity or hepatic PDFF, but only in small intestinal permeability.

This evidence suggests that FMT may provide therapeutic benefit in NAFLD, and at least three clinical trials examining FMT in adults with biopsy-confirmed NASH are actively recruiting subjects (Clinicaltrials.gov, NCT02469272, NCT03803540, NCT02721264).

The pathogenesis of primary sclerosing cholangitis (PSC) is still largely unclear ^[48]. Although genetic and environmental factors have been advocated, the association with inflammatory bowel diseases (IBD) in up to 70% of cases suggests a crucial role of the gut-liver axis. Gut microbiota composition and metabolic function, as well as the systemic and local immune response related to gut barrier permeability and bacterial translocation, can contribute to cholangiocytes injury, inflammation, and progression of fibrosis. Moreover, studies in animal models have demonstrated that enteric dysbiosis can lead to PSC-like alterations in the liver ^[49].

A specific gut microbiota signature allows us to discriminate PSC patients from healthy controls, independently of the association with IBD ^[50]. PSC patients show a reduced bacterial diversity and three bacterial genera, i.e. *Enterococcus*, *Fusobacterium*, and *Lactobacillus*, have been found to be significantly over-represented in PSC patients compared with healthy controls, independently of the severity of liver fibrosis, a previous history of liver transplantation, the concomitant presence of IBD, or ongoing treatment with ursodeoxycholic acid (UDCA) ^[50]. Indeed, gut-homing cells, T lymphocytes normally located in the lamina propria of the small intestine, and characterized by the expression of specific adhesion molecules, such as CCL25 and MadCAM-1, have been found in explant livers from patients with PSC ^[51]. This finding can be explained by the expression of adhesion molecules also in the hepatic sinusoids, which can favor the recruitment of gut-homing T cells in patients with PSC and contribute to the progression of biliary damage.

Interesting data have opened the field to the use of FMT in PSC patients (**Table 1**). An open-label pilot study evaluated the safety and efficacy (defined as a decrease in alkaline phosphatase [ALP] serum levels > 50%) of FMT in patients with PSC and concurrent IBD (**Table 1**). All 10 patients included in the study received FMT from a single donor by colonoscopy without the administration of antibiotics before the procedure. The analysis of stool samples highlighted that FMT was able to increase bacterial diversity and the strength of the bacterial engraftment correlated with the decrease in ALP levels.

Since enteric but not colonic dysbiosis leads to hepatobiliary inflammation in PSC animal models, the upper small bowel could represent the ideal route for FMT in patients with PSC, as successfully demonstrated in a recent case report (**Table 1**) ^[22]. Hopefully, future investigations will further clarify this point.

However, whether these alterations are the cause or consequence of liver disease is still unknown. Gut microbiota contributes to maintaining immune homeostasis, so it has been supposed that dysbiosis can trigger hepatic immune dysregulation through different mechanisms, such as cross-reactivity and molecular mimicry ^[52]. Furthermore, gut microbiota plays a pivotal role in the regulation of enterohepatic circulation of bile acids. Recent evidence underlines the association between dysbiosis and altered serum and fecal bile acid profile in PBC patients ^[53].

analyzed the difference between the gut microbiota of 60 patients with treatment naive PBC compared to 80 healthy controls, and then evaluated the modifications after treatment with UDCA. Treatment naive PBC patients had a reduced gut microbiota alpha-diversity compared with healthy controls, a decreased abundance of Bacteroidetes, and an increase in Fusobacteria and Proteobacteria. Interestingly, the evaluation of the gut microbiota profile after treatment with UDCA showed a reduction of *Haemophilus* spp., and *Pseudomonas* spp., and an increase of bacterial genera that were enriched in controls (*Bacteroides*, *Sutterella* spp.).

According to the actual knowledge, the immunological alterations associated with the pathogenesis of autoimmune hepatitis (AIH) are triggered by the interaction between genetic predisposition and environmental factors. In a recent study, Wei et al. analyzed the gut microbiota composition in steroid-naïve AIH compared to healthy controls ^[54]. The results demonstrated a decrease in gut microbiota diversity and an increased abundance of *Veillonella*, which was strongly associated with the severity of liver inflammation. The authors also built a model able to distinguish patients with AIH from healthy controls based on the gut microbiota composition, in particular on the combination of *Veillonella*, *Lactobacillus*, *Oscillospira*, and *Clostridiales*.

At present, no study has evaluated the efficacy and safety of FMT in patients with PBC or AIH.

4. Future Perspectives

The gut microbiota plays a crucial role in the modulation of the immune system and the inflammatory response, and is also involved in the regulation of several metabolic pathways. In the last few years, several studies have shown a link between chronic liver disease and the gut microbiota. Even though our understanding of the interaction between the gut and the liver is still incomplete, dysbiosis seems to be the mainstay of chronic liver disease at any stage. The dynamic changes of the gut microbiota play an important role in the initiation and progression of liver injury, and probably represent the first hit in specific settings, such as NAFLD.

Microbial signatures used in addition to clinical parameters can help in early diagnosis and in the avoidance of invasive diagnostic procedures. A shift in the gut microbiota composition during patients' follow-up or during the course of hospitalization could help to identify patients at high risk of unfavorable clinical evolution. Nevertheless, targeted approaches in the modulation of the gut microbiota may be more effective than the use of broad-spectrum antibiotics or conventional probiotics. In this regard, FMT is the most powerful tool to reset the gut microbiota derangement consequent to chronic liver disease, and should be implemented in daily clinical practice to act synergistically with conventional medical therapy.

At present, there are no standardized guidelines regarding the indications and the choice of the ideal FMT procedure to be used in clinical practice in patients with chronic liver disease. Although endoscopic techniques are reasonably safe, they are costly, invasive, they have potential procedural risks, and their repeatability over time may be limited. Enemas can fail to deliver fecal material throughout the colon if retention of the instilled material is not adequate. However further studies are needed to identify the ideal method of FMT administration in patients with chronic liver disease.

References

1. Qin, N.; Yang, F.; Li, A.; Prifti, E.; Chen, Y.; Shao, L.; Guo, J.; Le Chatelier, E.; Yao, J.; Wu, L.; et al. Alterations of the human gut microbiome in liver cirrhosis. *Nature* 2014, 513, 59–64.
2. Acharya, C.; Sahingur, S.E.; Bajaj, J.S. Microbiota, cirrhosis, and the emerging oral-gut-liver axis. *JCI Insight* 2017, 2, e94416.
3. Ridlon, J.M.; Kang, D.J.; Hylemon, P.B.; Bajaj, J.S. Bile acids and the gut microbiome. *Curr. Opin. Gastroenterol.* 2014, 30, 332–338.
4. Ridlon, J.M.; Harris, S.C.; Bhowmik, S.; Kang, D.-J.; Hylemon, P.B. Consequences of bile salt biotransformations by intestinal bacteria. *Gut Microbes* 2016, 7, 22–39.
5. Nicoletti, A.; Ponziani, F.R.; Biolato, M.; Valenza, V.; Marrone, G.; Sganga, G.; Gasbarrini, A.; Miele, L.; Grieco, A. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. *World J. Gastroenterol.* 2019, 25, 4814–4834.
6. Bajaj, J.S. The role of microbiota in hepatic encephalopathy. *Gut Microbes* 2014, 5, 397–403.
7. Schnabl, B.; Brenner, D.A. Interactions Between the Intestinal Microbiome and Liver Diseases. *Gastroenterology* 2015, 146, 1513–1524.
8. Kakiyama, G.; Pandak, W.M.; Gillevet, P.M.; Heuman, D.M.; Daita, K.; Takei, H.; Nittono, H.; Ridlon, J.M.; White, M.B.; Noble, A.; et al. Modulation of the Fecal Bile Acid Profile by Gut Microbiota in Cirrhosis. *J. Hepatol.* 2014, 58, 949–955.
9. Gómez-Hurtado, I.; Such, J.; Sanz, Y.; Francés, R. Gut microbiota-related complications in cirrhosis. *World J. Gastroenterol.* 2014, 20, 15624.
10. Rai, R.; Saraswat, V.A.; Dhiman, R.K. Gut Microbiota: Its Role in Hepatic Encephalopathy. *J. Clin. Exp. Hepatol.* 2015, 5, S29–S36.
11. Riordan, S.M.; Williams, R. Gut Flora and Hepatic Encephalopathy in Patients with Cirrhosis. *N. Engl. J. Med.* 2010, 362, 1140–1142.
12. Bajaj, J.S.; Sikaroodi, M.; Shamsaddini, A.; Henseler, Z.; Santiago-Rodriguez, T.; Acharya, C.; Fagan, A.; Hylemon, P.B.; Fuchs, M.; Gavis, E.; et al. Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. *Gut* 2020, 70, 1162–1173.
13. Bajaj, J.S.; Fagan, A.; Gavis, E.A.; Kassam, Z.; Sikaroodi, M.; Gillevet, P.M. Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis. *Gastroenterology* 2019, 156, 1921–1923.
14. Bajaj, J.S.; Salzman, N.H.; Acharya, C.; Sterling, R.K.; White, M.B.; Gavis, E.A.; Fagan, A.; Hayward, M.; Holtz, M.L.; Matherly, S.; et al. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. *Hepatology* 2019, 70, 1690–1703.
15. Bajaj, J.S.; Kassam, Z.; Fagan, A.; Gavis, E.A.; Liu, E.; Cox, I.J.; Kheradman, R.; Heuman, D.; Wang, J.; Gurry, T.; et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial: Bajaj et al. *Hepatology* 2017, 66, 1727–1738.
16. Ren, Y.-D.; Ye, Z.-S.; Yang, L.-Z.; Jin, L.-X.; Wei, W.-J.; Deng, Y.-Y.; Chen, X.-X.; Xiao, C.-X.; Yu, X.-F.; Xu, H.-Z.; et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy. *Hepatology* 2017, 65, 1765–1768.

17. Chauhan, A.; Kumar, R.; Sharma, S.; Mahanta, M.; Vayuru, S.K.; Nayak, B.; Kumar, S. Fecal Microbiota Transplantation in Hepatitis B e Antigen-Positive Chronic Hepatitis B Patients: A Pilot Study. *Dig. Dis. Sci.* 2021, 66, 873–880.
18. Philips, C.A.; Pande, A.; Shasthry, S.M.; Jamwal, K.D.; Khillan, V.; Chandel, S.S.; Kumar, G.; Sharma, M.K.; Maiwall, R.; Jindal, A.; et al. Healthy Donor Fecal Microbiota Transplantation in Steroid-Ineligible Severe Alcoholic Hepatitis: A Pilot Study. *Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc.* 2017, 15, 600–602.
19. Philips, C.A.; Phadke, N.; Ganesan, K.; Ranade, S.; Augustine, P. Corticosteroids, nutrition, pentoxifylline, or fecal microbiota transplantation for severe alcoholic hepatitis. *Indian J. Gastroenterol.* 2018, 37, 215–225.
20. Craven, L.; Rahman, A.; Nair Parvathy, S.; Beaton, M.; Silverman, J.; Qumosani, K.; Hramiak, I.; Hegele, R.; Joy, T.; Meddings, J.; et al. Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. *Am. J. Gastroenterol.* 2020, 115, 1055–1065.
21. Allegretti, J.R.; Kassam, Z.; Carrellas, M.; Mullish, B.H.; Marchesi, J.R.; Pechlivanis, A.; Smith, M.; Gerardin, Y.; Timberlake, S.; Pratt, D.S.; et al. Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. *Am. J. Gastroenterol.* 2019, 114, 1071–1079.
22. Philips, C.A.; Augustine, P.; Phadke, N. Healthy Donor Fecal Microbiota Transplantation for Recurrent Bacterial Cholangitis in Primary Sclerosing Cholangitis—A Single Case Report. *J. Clin. Transl. Hepatol.* 2018, 6, 438–441.
23. Zeng, Y.; Chen, S.; Fu, Y.; Wu, W.; Chen, T.; Chen, J.; Yang, B.; Ou, Q. Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. *J. Viral Hepat.* 2020, 27, 143–155.
24. Wang, J.; Wang, Y.; Zhang, X.; Liu, J.; Zhang, Q.; Zhao, Y.; Peng, J.; Feng, Q.; Dai, J.; Sun, S.; et al. Gut Microbial Dysbiosis Is Associated with Altered Hepatic Functions and Serum Metabolites in Chronic Hepatitis B Patients. *Front. Microbiol.* 2017, 8, 2222.
25. Chen, Z.; Xie, Y.; Zhou, F.; Zhang, B.; Wu, J.; Yang, L.; Xu, S.; Stedtfeld, R.; Chen, Q.; Liu, J.; et al. Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. *Front. Microbiol.* 2020, 11, 383.
26. Yang, X.-A.; Lv, F.; Wang, R.; Chang, Y.; Zhao, Y.; Cui, X.; Li, H.; Yang, S.; Li, S.; Zhao, X.; et al. Potential role of intestinal microflora in disease progression among patients with different stages of Hepatitis B. *Gut Pathog.* 2020, 12, 50.
27. Li, X.; Wu, S.; Du, Y.; Yang, L.; Li, Y.; Hong, B. Entecavir therapy reverses gut microbiota dysbiosis induced by hepatitis B virus infection in a mouse model. *Int. J. Antimicrob. Agents* 2020, 56, 106000.
28. Huang, H.; Ren, Z.; Gao, X.; Hu, X.; Zhou, Y.; Jiang, J.; Lu, H.; Yin, S.; Ji, J.; Zhou, L.; et al. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. *Genome Med.* 2020, 12, 102.
29. Preveden, T.; Scarpellini, E.; Milić, N.; Luzzza, F.; Abenavoli, L. Gut microbiota changes and chronic hepatitis C virus infection. *Expert Rev. Gastroenterol. Hepatol.* 2017, 11, 813–819.
30. Pérez-Matute, P.; Íñiguez, M.; Villanueva-Millán, M.J.; Recio-Fernández, E.; Vázquez, A.M.; Sánchez, S.C.; Morano, L.E.; Oteo, J.A. Short-term effects of direct-acting antiviral agents on inflammation and gut microbiota in hepatitis C-infected patients. *Eur. J. Intern. Med.* 2019, 67, 47–58.
31. Inoue, T.; Nakayama, J.; Moriya, K.; Kawaratani, H.; Momoda, R.; Ito, K.; Iio, E.; Nojiri, S.; Fujiwara, K.; Yoneda, M.; et al. Gut Dysbiosis Associated With Hepatitis C Virus Infection. *Clin. Infect. Dis.* 2018, 67, 869–877.
32. Sultan, S.; El-Mowafy, M.; Elgaml, A.; El-Mesery, M.; El Shabrawi, A.; Elegezy, M.; Hammami, R.; Mottawea, W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection. *ACS Infect. Dis.* 2020.
33. Bajaj, J.S.; Sterling, R.K.; Betrapally, N.S.; Nixon, D.E.; Fuchs, M.; Daita, K.; Heuman, D.M.; Sikaroodi, M.; Hylemon, P.B.; White, M.B.; et al. HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients. *Aliment. Pharmacol. Ther.* 2016, 44, 638–643.
34. Ponziani, F.R.; Putignani, L.; Paroni Sterbini, F.; Petito, V.; Picca, A.; Del Chierico, F.; Reddel, S.; Calvani, R.; Marzetti, E.; Sanguinetti, M.; et al. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. *Aliment. Pharmacol. Ther.* 2018, 48, 1301–1311.
35. Wellhöner, F.; Döschner, N.; Woelfl, F.; Vital, M.; Plumeier, I.; Kahl, S.; Potthoff, A.; Manns, M.P.; Pieper, D.H.; Cornberg, M.; et al. Eradication of chronic HCV infection: Improvement of dysbiosis only in patients without liver cirrhosis. *Hepatology* 2021.

36. Vassallo, G.; Mirijello, A.; Ferrulli, A.; Antonelli, M.; Landolfi, R.; Gasbarrini, A.; Addolorato, G. Review article: Alcohol and gut microbiota—the possible role of gut microbiota modulation in the treatment of alcoholic liver disease. *Aliment. Pharmacol. Ther.* 2015, 41, 917–927.
37. Hartmann, P.; Seebauer, C.T.; Schnabl, B. Alcoholic Liver Disease: The Gut Microbiome and Liver Cross Talk. *Alcohol. Clin. Exp. Res.* 2015, 39, 763–775.
38. Bajaj, J.S. Alcohol, liver disease and the gut microbiota. *Nat. Rev. Gastroenterol. Hepatol.* 2019, 16, 235–246.
39. Llopis, M.; Cassard, A.M.; Wrzosek, L.; Bosch, L.; Bruneau, A.; Ferrere, G.; Puchois, V.; Martin, J.C.; Lepage, P.; Le Roy, T.; et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. *Gut* 2016, 65, 830–839.
40. Addolorato, G.; Ponziani, F.R.; Dionisi, T.; Mosoni, C.; Vassallo, G.A.; Sestito, L.; Petito, V.; Picca, A.; Marzetti, E.; Tarli, C.; et al. Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. *Liver Int. Off. J. Int. Assoc. Study Liver* 2020, 40, 878–888.
41. Boursier, J.; Mueller, O.; Barret, M.; Machado, M.; Fizzanne, L.; Araujo-Perez, F.; Guy, C.D.; Seed, P.C.; Rawls, J.F.; David, L.A.; et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. *Hepatology* 2016, 63, 764–775.
42. Beards, E.; Tuohy, K.; Gibson, G. Bacterial, SCFA and gas profiles of a range of food ingredients following in vitro fermentation by human colonic microbiota. *Anaerobe* 2010, 16, 420–425.
43. Painter, K.; Cordell, B.J.; Sticco, K.L. Auto-brewery Syndrome. In *StatPearls*; StatPearls Publishing: Treasure Island, FL, USA, 2021.
44. Loomba, R.; Seguritan, V.; Li, W.; Long, T.; Klitgord, N.; Bhatt, A.; Dulai, P.S.; Caussy, C.; Bettencourt, R.; Highlander, S.K.; et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. *Cell Metab.* 2017, 25, 1054–1062.
45. Oh, T.G.; Kim, S.M.; Caussy, C.; Fu, T.; Guo, J.; Bassirian, S.; Singh, S.; Madamba, E.V.; Bettencourt, R.; Richards, L.; et al. A Universal Gut-Microbiome-Derived Signature Predicts Cirrhosis. *Cell Metab.* 2020, 32, 878–888.
46. Ponziani, F.R.; Nicoletti, A.; Gasbarrini, A.; Pompili, M. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. *Ther. Adv. Med. Oncol.* 2019, 11, 1758835919848184.
47. Behary, J.; Amorim, N.; Jiang, X.-T.; Raposo, A.; Gong, L.; McGovern, E.; Ibrahim, R.; Chu, F.; Stephens, C.; Jebeili, H.; et al. Gut microbiota impact on the peripheral immune response in non-alcoholic fatty liver disease related hepatocellular carcinoma. *Nat. Commun.* 2021, 12, 187.
48. Lazaridis, K.N.; LaRusso, N.F. Primary Sclerosing Cholangitis. *N. Engl. J. Med.* 2016, 375, 1161–1170.
49. Lichtman, S.N.; Keku, J.; Clark, R.L.; Schwab, J.H.; Sartor, R.B. Biliary tract disease in rats with experimental small bowel bacterial overgrowth. *Hepatology* 1991, 13, 766–772.
50. Sabino, J.; Vieira-Silva, S.; Machiels, K.; Joossens, M.; Falony, G.; Ballet, V.; Ferrante, M.; Van Assche, G.; Van der Merwe, S.; Vermeire, S.; et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. *Gut* 2016, 65, 1681–1689.
51. Williamson, K.D.; Chapman, R.W. New Therapeutic Strategies for Primary Sclerosing Cholangitis. *Semin. Liver Dis.* 2016, 36, 5–14.
52. Tanaka, A.; Leung, P.S.C.; Gershwin, M.E. Pathogen infections and primary biliary cholangitis. *Clin. Exp. Immunol.* 2019, 195, 25–34.
53. Chen, W.; Wei, Y.; Xiong, A.; Li, Y.; Guan, H.; Wang, Q.; Miao, Q.; Bian, Z.; Xiao, X.; Lian, M.; et al. Comprehensive Analysis of Serum and Fecal Bile Acid Profiles and Interaction with Gut Microbiota in Primary Biliary Cholangitis. *Clin. Rev. Allergy Immunol.* 2020, 58, 25–38.
54. Wei, Y.; Li, Y.; Yan, L.; Sun, C.; Miao, Q.; Wang, Q.; Xiao, X.; Lian, M.; Li, B.; Chen, Y.; et al. Alterations of gut microbiome in autoimmune hepatitis. *Gut* 2020, 69, 569–577.